Following on from information provided to NICE by the company in September 2021 the appraisal of Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1543 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in September 2021 the appraisal of Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 21 October 2021 | Suspended. As you will be aware, the Department of Health and Social Care has asked NICE to conduct an appraisal of Eflornithine with sulindac for treating familial adenomatous polyposis. On 24 June 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for eflornithine. Therefore, the appraisal of Eflornithine with sulindac for treating familial adenomatous polyposis has been suspended on the technology appraisals work programme and timelines remain to be confirmed. Upon information received from the company we note that they have requested a re-examination of the European Medicines Agency (EMA) June 2021 opinion and therefore, we will continue to monitor the situation and will update interested parties as and when the situation changes. |
| 13 October 2020 (14:00) | Scoping workshop |
| 20 August 2020 - 18 September 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual